Replies to post #5725 on Halozyme Therapeutics Inc (HALO)

[jamtomorrow2]

Why as the Enhanze royalty rates will be cut dramatically between 2027 and 2030 after the Enhanze patents expire. The patents actually expire in 2024 but there’s a 3 year period before anyone else can launch a competitive product. Big Pharma have picked up on the patent expiry position hence the big drop in the royalty rate. This was partially explained in the Q&A - and Helen was clearly feeling very uncomfortable as this had never been explained before.

[Fred Kadiddlehopper]

Given that assumption, what would be a fair pps today?